指南与共识血栓与止血

抗凝药命名建议:国际血栓与止血学会抗凝控制科学标准化委员会更新通报

Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation.
指南 / 共识 · J Thromb Haemost · 2023-02-14

口服抗凝治疗已从维生素K拮抗剂扩展到直接凝血酶抑制剂和Xa因子抑制剂,统称「直接口服抗凝药」,为房颤和静脉血栓栓塞症等常见血栓性疾病防治的当前标准治疗。针对XI/XIa和XII/XIIa因子的药物正在研究中,国际血栓与止血学会抗凝控制科学标准化委员会组建写作组,建议抗凝药按给药途径和特定靶点命名(如口服XIa因子抑制剂)。

要点

  • 直接口服抗凝药是房颤和静脉血栓栓塞症等常见血栓性疾病防治的当前标准治疗。
  • 靶向XI/XIa和XII/XIIa因子的药物正在多种血栓和非血栓疾病中研究。
  • 写作组建议抗凝药按给药途径和特定靶点命名,如口服XIa因子抑制剂。

核心结论

  • 写作组建议抗凝药物按给药途径和特定靶点进行描述(如口服XIa因子抑制剂)。

研究设计与样本

  • 国际血栓与止血学会抗凝控制科学标准化委员会组建写作组,在更广泛血栓社区意见基础上提出命名建议。

主要发现

  • 口服抗凝治疗已从维生素K拮抗剂扩展到口服直接凝血酶抑制剂和Xa因子抑制剂,统称「直接口服抗凝药」。
  • 直接口服抗凝药是房颤和静脉血栓栓塞症等常见血栓性疾病预防和治疗的当前标准治疗。
  • 靶向XI/XIa和XII/XIIa因子的药物正在多种血栓和非血栓疾病(如遗传性血管性水肿)中研究。

关键数值与推荐

  • 写作组推荐抗凝药物按给药途径和特定靶点描述,示例为「口服XIa因子抑制剂」。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oral anticoagulation therapy has evolved beyond vitamin K antagonists to include oral direct thrombin inhibitors and factor Xa inhibitors. Collectively known as "direct oral anticoagulants," this class of medications represents the current standard of care for the prevention and treatment of common thrombotic disorders, including atrial fibrillation and venous thromboembolism. Medications that target factors XI/XIa and XII/XIIa are currently under investigation for several thrombotic and nonthrombotic conditions. Given that these emerging medications will likely have distinct risk-benefit profiles to the current direct oral anticoagulants, may have different routes of administration, and could be used for unique clinical conditions (e.g., hereditary angioedema), the International Society on Thrombosis and Haemostasis Subcommittee on Control of Anticoagulation assembled a writing group to make recommendations on the nomenclature of anticoagulant medications. With input from the broader thrombosis community, the writing group recommends that anticoagulant medications be described by the route of administration and specific targets (e.g., oral factor XIa inhibitor).

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Barnes GD, Ageno W, Castellucci LA, et al. Recommendation on the nomenclature for anticoagulants: updated communication from the International Society on Thrombosis and Haemostasis Scientific and Standardization Commitee on the Control of Anticoagulation. J Thromb Haemost. 2023. PMID: 36796485. doi:10.1016/j.jtha.2023.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。